GlassScriptPhysician profile
Brian J Paradowski
NPI 1114919834
$19,795.42
in general payments reported to CMS, 2019-2025
50 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $2,975 · 2021: $4,250 · 2022: $3,451 · 2023: $2,737 · 2024: $2,086 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,894 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,894.41 |
| Education | $133.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,928.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,271.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $2,156.24 | 2021-2025 | |
| Amgen INC. | $1,788.54 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,685.02 | 2019-2025 | |
| Lilly USA, LLC | $1,387.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $712.90 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.25 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $561.00 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $533.82 | 2019-2021 | |
| Esperion Therapeutics, INC. | $497.11 | 2020-2025 | Nexletol |
| Allergan, INC. | $483.91 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $434.78 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $403.00 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $388.60 | 2019-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Paradowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.